Amyl Therapeutics
The computed 12-month bankruptcy probability of Amyl Therapeutics is 1.0% (low). The 2024 annual accounts show equity of €5.56M and a net result of €-2.44M. Equity is shrinking by ~6.2% per year across the filed fiscal years. Its solvency ranks better than 69% of 42 sector peers (fiscal year 2024). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €5.56M |
| Net result | €-2.44M |
| Staff (FTE) | 4.6 |
| Better than sector | 69% |
Mixed profile: strong on solvency, weaker on profitability.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 66.3% | 53.6% | |
| Net result | €-2.44M | €-16k | |
| Equity | €5.56M | €644k | |
| Gross operating margin | €-872k | €7k | |
| Total assets | €8.39M | €1.71M |
| Fiscal year | 2024 |
|---|---|
| Deposit | volledig |
| Revenue | - |
| EBITDA | €-1.37M |
| Net profit | €-2.44M |
| Cash flow | €87k |
| Staff costs | €500k |
| Income taxes | €-99k |
| Dividends | - |
| Total assets | €8.39M |
| Equity | €5.56M |
| Debt | €2.82M |
| of which ≤ 1y | €453k |
| of which > 1y | €2.23M |
| Working capital | €2.67M |
| Employees (FTE) | 4.6 |
| 2024 | |
|---|---|
| Current ratio | 6.89 |
| Quick ratio | 6.89 |
| Working capital ratio | 31.8% |
| Solvency | 66.3% |
| Debt / equity | 0.51 |
| Long-term debt ratio | 0.40 |
| Interest coverage | -9.48 |
| Gross margin | - |
| Net margin | - |
| ROA | -29.1% |
| ROE | -43.8% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €8.39M |
| Fixed assets | 21/28 | €5.27M |
| Intangible fixed assets | 21 | €5.02M |
| Tangible fixed assets | 22/27 | €246k |
| Current assets | 29/58 | €3.12M |
| Amounts receivable within one year | 40/41 | €823k |
| Cash & bank | 54/58 | €2.28M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €8.39M |
| Equity | 10/15 | €5.56M |
| Contributions / capital | 10/11 | €5.97M |
| Accumulated profits (losses) | 14 | €-409k |
| Amounts payable | 17/49 | €2.82M |
| Amounts payable after one year | 17 | €2.23M |
| Amounts payable within one year | 42/48 | €453k |
| Trade debts payable within one year | 44 | €392k |
| Income statement | ||
| Gross operating margin | 9900 | €-872k |
| Operating result | 9901 | €-3.90M |
| Financial income | 75 | €1.51M |
| Financial charges | 65 | €145k |
| Result before taxes | 9903 | €-2.54M |
| Income taxes | 67/77 | €-99k |
| Net result for the period | 9904 | €-2.44M |
| Result to be appropriated | 9905 | €-2.44M |
-
Current13-04-2021 → present
-
Current13-04-2021 → present
-
SWISSVENTION PARTNERS GMBHLegal entityDirector· perm. rep.: GROS FlorentState Gazette act 21323489 (13-04-2021)Current13-04-2021 → present
-
Current13-04-2021 → present
-
NOSHAQ PARTNERSLegal entityDirector· perm. rep.: TOUNSI AmelState Gazette act 21369288 (26-11-2021)Current29-03-2021 → present
-
VACCIBIO CONSULTINGLegal entityManaging director· perm. rep.: Pierre VandepapelièreState Gazette act 21065880 (03-06-2021)Current29-03-2021 → present
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| PwC Réviseurs d'Entreprises SRLCurrent Statutory auditor · represented by Mélanie Adorante |
- | 04-04-2023 → present |
| Moore Audit Company auditor · represented by Stijn Van Hout succeeded by PwC Réviseurs d'Entreprises SRL in 2023 |
- | 29-03-2021 → 04-04-2023 |
| NACE primary | Speur- en ontwikkelingswerk op biotechnologisch gebied(72101) |
| Legal form | Private limited company(610) |
| Incorporation | 26-11-2020 |
| Status | Active |
| Postal code | 4000 |
Each band states what its claims rest on. A board seat is influence over the board, not ownership. Court mandates (receiver, interim administrator) and liquidation mandates do not link companies and are therefore absent here; they belong under Directors & mandates.
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62042B0366/00B003 | Wallonia | 1.9 ha | - | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
22-12-2025 Transaction in capital or shares
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
}
}04-02-2025 Transaction in capital or shares
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
}
}14-05-2024 Registered office moved from Seraing to Liège
- Rue dèl Rodge Cinse 98, 4102 Seraing → Boulevard Patience et Beaujonc 3, 4000 Liège
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Li\u00E8ge",
"region": null,
"street": "Boulevard Patience et Beaujonc",
"country": "BE",
"postcode": "4000",
"box_number": null,
"street_number": "3"
},
"old_address": {
"city": "Seraing",
"region": null,
"street": "Rue d\u00E8l Rodge Cinse",
"country": "BE",
"postcode": "4102",
"box_number": null,
"street_number": "98"
},
"effective_date": "2024-03-12",
"evidence_quote": "Le conseil d\u0027administration d\u00E9cide de transf\u00E9rer le si\u00E8ge de la soci\u00E9t\u00E9 de la Rue d\u00E8l Rodge Cinse 98 \u00E0 4102 Seraing vers le Boulevard Patience et Beaujonc 3 \u00E0 4000 Li\u00E8ge. Le transfert prendra effet \u00E0 partir du 12 mars 2024."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
}
}12-02-2024 Transaction in capital or shares
Technical details
{
"events": [
{
"kind": "warrant_issuance",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Geoffrey GAUTHY",
"firm_city": null,
"firm_name": "GAUTHY, JACQUES \u0026 ROLANS \u2013 Soci\u00E9t\u00E9 Notariale",
"office_city": "Herstal",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2024-02-12",
"filing_date": "2024-02-08",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2024-02-08",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": null,
"firm_name": "PwC",
"ibr_number": null,
"mission_type": "apport_nature",
"individual_name": "ADORANTE M\u00E9lanie"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "Amyl Therapeutics",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition de l\u2019assembl\u00E9e comprenant les procurations, le rapport de l\u2019organe d\u2019administration et le rapport du commissaire",
"la coordination des statuts"
],
"shareholders_after": [],
"share_classes_after": []
}12-09-2023 Capital increase of €2,000,000
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 2000000,
"currency": "EUR",
"after_eur": null,
"delta_eur": 2000000,
"before_eur": null,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-09-08",
"evidence_quote": "\u00E0 lib\u00E9rer imm\u00E9diatement \u00E0 concurrence de la totalit\u00E9 par un apport en num\u00E9raire de deux millions d\u2019euros (2.000.000,00 \u20AC) par Monsieur Evren Ucok.",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
}
}12-04-2023 Capital increase of €1,500,000
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 1500000.0,
"currency": "EUR",
"after_eur": null,
"delta_eur": 1500000.0,
"before_eur": null,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-04-04",
"evidence_quote": "lib\u00E9rer imm\u00E9diatement \u00E0 concurrence de la totalit\u00E9 des apports en num\u00E9raire totaux d\u2019un million cinq cent mille euros (1.500.000,00 \u20AC)",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
}
}04-04-2023 Mélanie Adorante appointed as statutory auditor
- Mélanie Adorante, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "M\u00E9lanie Adorante",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "SRL PwC Reviseurs d\u0027Entreprises",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme la SRL PwC Reviseurs d\u0027Entreprises, ayant son si\u00E8ge social \u00E0 1831 Diegem, Culliganlaan 5, comme commissaire pour un terme de trois ans. Cette soci\u00E9t\u00E9 d\u00E9signe Madame M\u00E9lanie Adorante, r\u00E9viseur d\u0027entreprises, pour la repr\u00E9senter et la charge de l\u0027exercice de ce mandat au nom"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
}
}30-06-2022 Transaction in capital or shares
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
}
}26-11-2021 TOUNSI Amel reappointed as director
- TOUNSI Amel, Bestuurder
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "TOUNSI Amel",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "NOSHAQ PARTNERS",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-03-29",
"evidence_quote": "L\u0027assembl\u00E9e constate qu\u0027a d\u00E8s lors \u00E9t\u00E9 nomm\u00E9e comme administrateur de la Soci\u00E9t\u00E9 avec effet au 29 mars 2021 : la soci\u00E9t\u00E9 coop\u00E9rative \u00E0 responsabilit\u00E9 limit\u00E9e NOSHAQ PARTNERS, ayant son si\u00E8ge \u00E0 4000 Li\u00E8ge, Rue Lambert-Lombard 3, repr\u00E9sent\u00E9e par son repr\u00E9sentant permanent, Madame TOUNSI Amel, domicili"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
}
}03-06-2021 2 directors appointed
- Pierre Vandepapelière, Gedelegeerd bestuurder
- Florent Gros, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Pierre Vandepapeli\u00E8re",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0568548672",
"name": "Vaccibio Consulting",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-03-29",
"evidence_quote": "Le conseil d\u0027administration a d\u00E9cid\u00E9 de nommer Vaccibio Consulting, une soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e, ayant son si\u00E8ge \u00E0 5021 Namur (Boninne), Rue du Long-Sart 38, inscrite au registre des personnes morales sous le num\u00E9ro 0568.548.672, repr\u00E9sent\u00E9e de fa\u00E7on permanente par M. Pierre Vandepapeli\u00E8re,"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Florent Gros",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0734792024",
"name": "Swissvention Partners GmbH",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-03-29",
"evidence_quote": "Le conseil d\u0027administration a d\u00E9cid\u00E9 de nommer Swissvention Partners GmbH, une soci\u00E9t\u00E9 de droit suisse, ayant son si\u00E8ge \u00E0 4055 Basel, Strassburgerallee 107, inscrite au registre des personnes morales sous le num\u00E9ro 0734.792.024, repr\u00E9sent\u00E9e de fa\u00E7on permanente par M. Florent Gros en qualit\u00E9 de pr\u00E9si"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
}
}13-04-2021 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2021-03-29",
"legal_form_change": false
},
"bedrijfsrevisor": {
"quote": "Le rapport du r\u00E9viseur d\u0027entreprises en date du 25 mars 2021, \u00E9tabli par la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e Moore Audit, ayant son si\u00E8ge \u00E0 Schali\u00EBnstraat 3, 2000 Anvers, repr\u00E9sent\u00E9e par M. Stijn Van Hout, inscrite au registre des personnes morales sous le num\u00E9ro 0453.925.059",
"firm_kbo": "0453.925.059",
"firm_name": "Moore Audit",
"ibr_number": null,
"individual_name": "Stijn Van Hout"
},
"subject_company": {
"kbo": "0758.775.372",
"name_full": "AMYL THERAPEUTICS",
"legal_form": "SRL"
},
"signature_regime": "joint_by_class",
"special_mandates": [
{
"quote": "L\u0027assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Ma\u00EEtre Louisa Vandepitte, Ma\u00EEtre Maxine Daems ou tout autre avocat ou collaborateur du cabinet NautaDutilh, situ\u00E9 \u00E0 1000 Bruxelles, Chauss\u00E9e de La Hulpe 120, chacun agissant s\u00E9par\u00E9ment, ainsi qu\u0027\u00E0 leurs employ\u00E9s, pr\u00E9pos\u00E9s et mandataires, avec droit de substitution, afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer l\u0027inscription/la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
"holder_kbo": null,
"holder_name": "Ma\u00EEtre Louisa Vandepitte",
"scope_categories": [
"KBO",
"tax",
"filing"
],
"with_substitution": true
},
{
"quote": "L\u0027assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Ma\u00EEtre Louisa Vandepitte, Ma\u00EEtre Maxine Daems ou tout autre avocat ou collaborateur du cabinet NautaDutilh, situ\u00E9 \u00E0 1000 Bruxelles, Chauss\u00E9e de La Hulpe 120, chacun agissant s\u00E9par\u00E9ment, ainsi qu\u0027\u00E0 leurs employ\u00E9s, pr\u00E9pos\u00E9s et mandataires, avec droit de substitution, afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer l\u0027inscription/la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
"holder_kbo": null,
"holder_name": "Ma\u00EEtre Maxine Daems",
"scope_categories": [
"KBO",
"tax",
"filing"
],
"with_substitution": true
},
{
"quote": "L\u0027assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Ma\u00EEtre Louisa Vandepitte, Ma\u00EEtre Maxine Daems ou tout autre avocat ou collaborateur du cabinet NautaDutilh, situ\u00E9 \u00E0 1000 Bruxelles, Chauss\u00E9e de La Hulpe 120, chacun agissant s\u00E9par\u00E9ment, ainsi qu\u0027\u00E0 leurs employ\u00E9s, pr\u00E9pos\u00E9s et mandataires, avec droit de substitution, afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer l\u0027inscription/la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
"holder_kbo": null,
"holder_name": "NautaDutilh",
"scope_categories": [
"KBO",
"tax",
"filing"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}30-11-2020 Incorporation of a new SRL
Technical details
{
"kind": "oprichting",
"seat": "Quai Banning 6, 4000 Li\u00E8ge",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": null,
"name": "VACCIBIO CONSULTING"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "nominatives",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "VACCIBIO CONSULTING",
"contribution_type": "cash",
"amount_paid_in_eur": 1260,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 315000,
"amount_subscribed_eur": 1260,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "SWISSVENTION PARTNERS GMBH"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "nominatives",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "SWISSVENTION PARTNERS GMBH",
"contribution_type": "cash",
"amount_paid_in_eur": 540,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 135000,
"amount_subscribed_eur": 540,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 2000,
"subject_company": {
"kbo": "0758.775.372",
"name_full": "Amyl Therapeutics",
"legal_form": "SRL"
},
"initial_directors": [],
"incorporation_date": "2020-11-25",
"post_incorporation_mandates": []
}| Legal nameFR | Amyl Therapeutics |